Skip to main content

Advertisement

Log in

Therapy assessment in prostate cancer using choline and PSMA PET/CT

  • Review Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

While PET with non-FDG tracers (mainly choline and Ga-PSMA) has commonly been used for restaging in men with biochemically recurrent prostate cancer, as well as for primary staging, it is only recently that a few preliminary studies have addressed the possible use of PET for monitoring the response to systemic therapy of metastatic disease, especially innovative treatments such as abiraterone and enzalutamide. This article aims to evaluate the role of PET imaging with different non-FDG radiotracers for assessment of therapy in advanced prostate cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.

    Article  CAS  PubMed  Google Scholar 

  2. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.

    Article  PubMed  Google Scholar 

  3. Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.

    Article  PubMed  Google Scholar 

  4. Eisenberger MA, Walsh PC. Early androgen deprivation for prostate cancer? N Engl J Med. 1999;341:1837–8.

    Article  CAS  PubMed  Google Scholar 

  5. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33–9.

    Article  PubMed  Google Scholar 

  6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

    Article  CAS  PubMed  Google Scholar 

  7. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.

    Article  PubMed  PubMed Central  Google Scholar 

  8. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.

    Article  CAS  PubMed  Google Scholar 

  10. Carvalhal GF, Daudi SN, Kan D, Mondo D, Roehl KA, Loeb S, et al. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology. 2010;76:1072–6.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32:671–7.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014;6:254ra125.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Burgio SL, et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(1):39–43.

    Article  PubMed  Google Scholar 

  15. Pezaro CJ, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65:270–3.

    Article  CAS  PubMed  Google Scholar 

  16. Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016:1–38. doi:10.1200/JCO.2015.64.2702.

  17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  PubMed  Google Scholar 

  18. Messiou C, Cook G, De Souza NM. Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer. 2009;101:1225–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Koh DM, et al. Whole-body diffusion-weighted MRI: ips, tricks, and pitfalls. AJR Am J Roentgenol. 2012;199:252–62.

    Article  PubMed  Google Scholar 

  20. Padhani AR, Lecouvet FE, Tunariu N. METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of Multiorgan involvement in advanced prostate cancer. Eur Urol. 2017;71(1):81–92.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Ackerstaff E, Pflug BR, Nelson JB, et al. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001;61:3599–603.

    CAS  PubMed  Google Scholar 

  22. Graziani T, Ceci F, Castellucci P, et al. (11)C-choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. Eur J Nucl Med Mol Imaging. 2016;43(11):1971–9.

    Article  CAS  PubMed  Google Scholar 

  23. Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008;179:906–10.

    Article  PubMed  Google Scholar 

  24. Ceci F, Castellucci P, Graziani T, et al. (11)C-choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. Eur J Nucl Med Mol Imaging. 2016;43(1):84–91.

    Article  CAS  PubMed  Google Scholar 

  25. Schwarzenböck SM, Eiber M, Kundt G, Retz M, Sakretz M, Kurth J, et al. Eur J Nucl Med Mol Imaging. 2016; doi:10.1007/s00259-016-3439-9.

  26. De Giorgi U, Caroli P, Scarpi E, et al. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging. 2015;42(8):1276–83.

    Article  CAS  PubMed  Google Scholar 

  27. De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E, Fabbri F, Carretta E, Amadori D, Paganelli G, Matteucci F. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget. 2014;5(23):12448–58.

  28. Maines F, Caffo O, Donner D, et al. Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. Future Oncol. 2016;12:333–42.

    Article  CAS  PubMed  Google Scholar 

  29. Oprea-Lager DE, Kramer G, van de Ven PM, et al. Repeatability of quantitative 18F-Fluoromethylcholine PET/CT studies in prostate cancer. J Nucl Med. 2016;57(5):721–7.

    Article  PubMed  Google Scholar 

  30. Giovacchini G, Picchio M, Garcia-Parra R, et al. 11C-choline PET/CT predicts prostate cancer–specific survival in patients with biochemical failure during androgen-deprivation therapy. J Nucl Med. 2014;55:233–41.

    Article  CAS  PubMed  Google Scholar 

  31. Giovacchini G, Incerti E, Mapelli P, et al. [11C]choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2015;42:877–84.

    Article  CAS  PubMed  Google Scholar 

  32. Kwee SA, Lim J, Watanabe A, et al. Prognosis related to metastatic burden measured by 18F-fluorocholine PET/CT in castration-resistant prostate cancer. J Nucl Med. 2014;55:905–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Bach-Gansmo T, Nanni C, Nieh PT, et al. Multisite experience of the safety, detection rate and diagnostic performance of Fluciclovine ((18)F) positron emission tomography/computerized tomography imaging in the staging of biochemically recurrent prostate cancer. J Urol. 2017;197(3 Pt 1):676–83.

    Article  PubMed  Google Scholar 

  34. Fendler WP, Eiber M, Beheshti M, et al. (68)Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014–24.

    Article  PubMed  Google Scholar 

  35. Barinka C, Rojas C, Slusher B, et al. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem. 2012;19:856–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Meller B, Bremmer F, Sahlmann CO, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5(1):66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Francesco Ceci.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Considering the retrospective design of the study, formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ceci, F., Herrmann, K., Hadaschik, B. et al. Therapy assessment in prostate cancer using choline and PSMA PET/CT. Eur J Nucl Med Mol Imaging 44 (Suppl 1), 78–83 (2017). https://doi.org/10.1007/s00259-017-3723-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-017-3723-3

Keywords

Navigation